AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24788619 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triple disease-modifying antirheumatic drug therapy (iTDT) with glucocorticoids intramuscularly (arm A)
Number of subjects: 281
Study 24788619 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triple disease-modifying antirheumatic drug therapy (iTDT) with oral glucocorticoids tapering (arm B)
Number of subjects: 281
Study 24788619 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy (iMM) with oral glucocorticoids (arm C)
Number of subjects: 281
Study 20449626 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic cyclophosphamide (MC)
Number of subjects: 88
Study 20449626 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 88
Study 20546699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT) for BZ Discontinuation
Number of subjects: 47
Study 20546699 — intervention group
Group type: COMPARATOR
Intervention: Taper alone
Number of subjects: 47
Study 20546699 — intervention group
Group type: COMPARATOR
Intervention: Taper plus relaxation
Number of subjects: 47
Study 18179324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoric participants in the easy condition
Number of subjects: 2
Study 18179324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondysphoric participants in the difficult condition
Number of subjects: 2
Study 16308444 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym (1 tablet for 6 kg weight, administered for 3 months)
Number of subjects: 27
Study 12585811 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 0
Study 12585811 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 10227638 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone (500 mg daily for 5 days, with a 10-day tapering period)
Number of subjects: 60
Study 10227638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10227638 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone
Number of subjects: 60
Study 8678176 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital/crisis respite care
Number of subjects: 197
Study 8678176 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 197
Study 8457123 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (0.5 g twice a day for 5 days)
Number of subjects: 106
Study 8457123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 8457123 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 106
Study 8457123 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate and Placebo
Number of subjects: 106
Study 3816511 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxen (500 mg twice a day for 60 days)
Number of subjects: 40
Study 3816511 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day for 60 days)
Number of subjects: 40
Study 30615071 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated Advance Care Planning (ACP) conversations
Number of subjects: 201
Study 30615071 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 201
Study 29361887 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Number of subjects: 0
Study 29361887 — intervention group
Group type: COMPARATOR
Intervention: Attention control case management group
Number of subjects: 0
Study 27802283 — intervention group
Group type: EXPERIMENTAL
Intervention: Zindagi SMS (daily SMS reminders)
Number of subjects: 2207
Study 27802283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 2207
Study 27802283 — intervention group
Group type: EXPERIMENTAL
Intervention: Zindagi SMS
Number of subjects: 2207
Study 27802283 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2207
Study 24992897 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (30 min) during performance (online tDCS)
Number of subjects: 20
Study 24992897 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS (30 min) before performance (offline tDCS)
Number of subjects: 20
Study 25091615 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled cardiovascular exercise (5 sessions a week of 40 minutes each for 10 weeks with a heart rate reserve of 40 to 80%)
Number of subjects: 34
Study 25091615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 21735214 — intervention group
Group type: EXPERIMENTAL
Intervention: IHH (hyperoxic-hypoxic group) - breathed pure oxygen (F(i)O(2)1.0) for 1 h, followed by hypoxic gas mixture (F(i)O(2)0.15) for 1 h
Number of subjects: 18
Study 21735214 — intervention group
Group type: COMPARATOR
Intervention: CON (control group) - breathed normoxic gas mixture (F(i)O(2)0.21) for 2 h
Number of subjects: 18
Study 19714275 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with modified Hagie pin
Number of subjects: 57
Study 19714275 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with sling for comfort
Number of subjects: 57
Study 17615468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pruritus intervention program (2 weeks)
Number of subjects: 43
Study 17615468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 15008768 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental infusion of oxytocin maintained after 5 cm dilation (Group A)
Number of subjects: 104
Study 15008768 — intervention group
Group type: COMPARATOR
Intervention: Incremental infusion of oxytocin discontinued at 5 cm dilation (Group B)
Number of subjects: 104
Study 11896107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 81
Study 11896107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 9578274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 102
Study 9578274 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 102
Study 8711499 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/Ifosfamide
Number of subjects: 357
Study 8711499 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment continuation (Epirubicin/Ifosfamide)
Number of subjects: 357
Study 8711499 — intervention group
Group type: COMPARATOR
Intervention: Treatment interruption (control)
Number of subjects: 357
Study 1925103 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 17
Study 1925103 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 17
Study 1925103 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17
Study 1925103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1925103 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 17
Study 7114338 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic screening with mammography and palpation of the breast
Number of subjects: 0
Study 7114338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study 31841793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive clinicoradiological follow-up
Number of subjects: 2261
Study 30415601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril‐valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Number of subjects: 881
Study 30415601 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (target dose, 10 mg twice daily)
Number of subjects: 881
Study 30415601 — intervention group
Group type: COMPARATOR
Intervention: Sacubitril‐valsartan vs. Enalapril
Number of subjects: 881
Study 30415601 — intervention group
Group type: COMPARATOR
Intervention: Sacubitril‐valsartan and Enalapril
Number of subjects: 881
Study 27538241 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 1255
Study 27538241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 27243927 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring device plus standard care
Number of subjects: 1927
Study 27243927 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1927
Study 24896818 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 1352
Study 24896818 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 1352
Study 24896818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1352
Study 22287674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate diet (22 g nitrate/kg DM)
Number of subjects: 16
Study 22287674 — intervention group
Group type: COMPARATOR
Intervention: Control diet (urea added to make isonitrogenous)
Number of subjects: 16
Study 19056319 — intervention group
Group type: EXPERIMENTAL
Intervention: Written stepwise instruction to optimize the Ramsay Scale
Number of subjects: 45
Study 17633136 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine
Number of subjects: 0
Study 17633136 — intervention group
Group type: COMPARATOR
Intervention: Voluven
Number of subjects: 0
Study 15134973 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial sextant biopsy
Number of subjects: 728
Study 15134973 — intervention group
Group type: EXPERIMENTAL
Intervention: Second screening visit after 4 years
Number of subjects: 728
Study 15134973 — intervention group
Group type: COMPARATOR
Intervention: Initial screening round
Number of subjects: 728
Study 15134973 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cases identified
Number of subjects: 728
Study 15134973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancers detected
Number of subjects: 728
Study 11813930 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 11813930 — intervention group
Group type: COMPARATOR
Intervention: Human NPH insulin
Number of subjects: 0
Study 9521197 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with acyclovir and/or ganciclovir
Number of subjects: 0
Study 9420671 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study 9420671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 20
Study 9420671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 20
Study 9420671 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise, Dipyridamole, Adenosine (all modes of stress)
Number of subjects: 20
Study 1870247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietetic-hygienic measures and hypolipidemic (mainly clofibrate and/or probucol) and antihypertensive (mainly beta-blockers and/or diuretics) drugs
Number of subjects: 1222
Study 6751091 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 40
Study 6751091 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5% and 1%
Number of subjects: 40
Study 6751091 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 40
Study 31214549 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 40
Study 31214549 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT (Control)
Number of subjects: 40
Study 28414899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2 μg·kg‐1, n = 71)
Number of subjects: 141
Study 28414899 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate (80 mg·kg‐1, n = 70)
Number of subjects: 141
Study 28414899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 141
Study 28414899 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate
Number of subjects: 141
Study 26283669 — intervention group
Group type: EXPERIMENTAL
Intervention: Head cooling for 72 hours starting within 6 hours of birth
Number of subjects: 234
Study 26283669 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 234
Study 23327504 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous-related helping (AAH)
Number of subjects: 226
Study 23327504 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting attendance
Number of subjects: 226
Study 21721351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) preconditioning consisting of two 30‐minute intervals of 100% oxygen at 2.4 ATA
Number of subjects: 81
Study 21721351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) preconditioning
Number of subjects: 81
Study 21721351 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control Group)
Number of subjects: 81
Study 19863880 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan neck catheter (Group A)
Number of subjects: 110
Study 19863880 — intervention group
Group type: COMPARATOR
Intervention: Tenckhoff catheter (Group B)
Number of subjects: 110
Study 19863880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 17200837 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 68
Study 17200837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15098212 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 0
Study 15098212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15098212 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop test (mechanical interruption)
Number of subjects: 0
Study 15098212 — intervention group
Group type: COMPARATOR
Intervention: Pressure-flow studies (Schäfer contractility nomogram)
Number of subjects: 0
Study 12413620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 1011
Study 12413620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 800 microg
Number of subjects: 1011
Study 12413620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 800 microg
Number of subjects: 1011
Study 9848486 — intervention group
Group type: COMPARATOR
Intervention: HVB bisacodyl suppositories
Number of subjects: 14
Study 9848486 — intervention group
Group type: EXPERIMENTAL
Intervention: PGB bisacodyl suppositories
Number of subjects: 14
Study 8029808 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 59
Study 8029808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 3141866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous provocative‐neutralization food test interpreted by skin response (IPFT SK)
Number of subjects: 37
Study 3141866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous provocative‐neutralization food test interpreted by symptom provocation (IPFT PR)
Number of subjects: 37
Study 3141866 — intervention group
Group type: COMPARATOR
Intervention: Double-blind IPFT results
Number of subjects: 37
Study 31197730 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system-based tobacco coach (internal care coordination)
Number of subjects: 639
Study 31197730 — intervention group
Group type: EXPERIMENTAL
Intervention: National quitline (external community referral)
Number of subjects: 639
Study 31197730 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 639
Study 27753246 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceed (oxidized regenerated cellulose)
Number of subjects: 99
Study 27753246 — intervention group
Group type: COMPARATOR
Intervention: Non‐Interceed (control group)
Number of subjects: 99
Study 25258197 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 58
Study 25258197 — intervention group
Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 58
Study 23135343 — intervention group
Group type: EXPERIMENTAL
Intervention: Colobreathe dry powder for inhalation (CDPI, one capsule containing colistimethate sodium 1,662,500 IU, twice daily)
Number of subjects: 380
Study 23135343 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhaler solution (TIS, 300 mg/5 ml, twice daily for three 28-day cycles)
Number of subjects: 380
Study 23135343 — intervention group
Group type: EXPERIMENTAL
Intervention: Colobreathe dry powder for inhalation (CDPI)
Number of subjects: 380
Study 23135343 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhaler solution (TIS)
Number of subjects: 380
Study 23135343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 380
Study 21536248 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic duct mass ligation during esophagectomy (prevention group)
Number of subjects: 653
Study 21536248 — intervention group
Group type: COMPARATOR
Intervention: Esophagectomy without thoracic duct mass ligation (preservation group)
Number of subjects: 653
Study 21536248 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of chylothorax
Number of subjects: 653
Study 21536248 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chylothorax management
Number of subjects: 653
Study 18047501 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA (139 units total; 17 sites/6 muscle groups)
Number of subjects: 61
Study 18047501 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA (open-label treatment months 4-6)
Number of subjects: 61
Study 18047501 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA
Number of subjects: 61
Study 18047501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16480401 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 (10 mg/kg, intravenous, 8-weekly through to week 32)
Number of subjects: 271
Study 16480401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 12716572 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions and written information
Number of subjects: 84
Study 12716572 — intervention group
Group type: COMPARATOR
Intervention: Written information only (Control)
Number of subjects: 84
Study 10855459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate 800 mg bid
Number of subjects: 196
Study 10855459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 9116778 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (900-1200 mg/day)
Number of subjects: 201
Study 9116778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 1590931 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sodium alginate
Number of subjects: 20
Study 1590931 — intervention group
Group type: COMPARATOR
Intervention: Porcine xenograft
Number of subjects: 20
Study 3897051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding screw plate
Number of subjects: 49
Study 3897051 — intervention group
Group type: COMPARATOR
Intervention: Sliding nail plate
Number of subjects: 49
Study 29528704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (Cholecalciferol) 50,000 IU in tablet form, monthly, for 1 yr
Number of subjects: 400
Study 29528704 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 400 IU in tablet form, monthly, for 1 yr
Number of subjects: 400
Study 26652193 — intervention group
Group type: EXPERIMENTAL
Intervention: START (STrAtegies for RelaTives), an eight-session, manual-based coping intervention
Number of subjects: 260
Study 26652193 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 260
Study 24407182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg every other day)
Number of subjects: 36
Study 24407182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22268128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital@Work intervention (VEP + Personal Vitality Coach)
Number of subjects: 730
Study 22268128 — intervention group
Group type: EXPERIMENTAL
Intervention: High compliance to yoga
Number of subjects: 730
Study 22268128 — intervention group
Group type: EXPERIMENTAL
Intervention: High compliance to workout sessions
Number of subjects: 730
Study 22268128 — intervention group
Group type: COMPARATOR
Intervention: Vital@Work intervention
Number of subjects: 730
Study 22268128 — intervention group
Group type: EXPERIMENTAL
Intervention: High workout compliance
Number of subjects: 730
Study 20604918 — intervention group
Group type: EXPERIMENTAL
Intervention: A-Part Gel
Number of subjects: 60
Study 20604918 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group
Number of subjects: 60
Study 17919141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 5 x 10(9) colony forming units b.i.d. for 12 weeks
Number of subjects: 102
Study 17919141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 17919141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 102
Study 16116007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg
Number of subjects: 0
Study 16116007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg
Number of subjects: 0
Study 16116007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg
Number of subjects: 0
Study 16116007 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline
Number of subjects: 0
Study 12183495 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine 1 h preexercise (Precaf)
Number of subjects: 20
Study 12183495 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 1 mg/kg caffeine every 20 min throughout steady-state (Durcaf)
Number of subjects: 20
Study 12183495 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 5 ml/kg Coca-Cola during steady-state and TT (Coke)
Number of subjects: 20
Study 12183495 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated, 6% CHO (Coke)
Number of subjects: 20
Study 12183495 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated, 6% CHO (control)
Number of subjects: 20
Study 12183495 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated, 11% CHO (Coke)
Number of subjects: 20
Study 12183495 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated, 11% CHO (Coke)
Number of subjects: 20